Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 05, 2022

SELL
$29.0 - $47.27 $3,190 - $5,199
-110 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $5,332 - $8,605
110 New
110 $6,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.77B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Smith Group Asset Management, LLC Portfolio

Follow Smith Group Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Group Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Group Asset Management, LLC with notifications on news.